Nanoprecipitation is more efficient than emulsion solvent evaporation method to encapsulate cucurbitacin I in PLGA nanoparticles

Saudi Pharmaceutical Journal

Volumn 22, Issue 3, 2014, Pages 219-222

  Alshamsan, Aws ^a  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

Cucurbitacin I; Emulsion solvent evaporation; Nanoparticles; Nanoprecipitation; PLGA

Indexed keywords

CUCURBITACIN; CUCURBITACIN I; NANOPARTICLE; POLYGLACTIN; UNCLASSIFIED DRUG;

AQUEOUS SOLUTION; ARTICLE; CRYSTALLIZATION; DRUG RETENTION; DRUG SOLUBILITY; EMULSION; EVAPORATION; HYDRODYNAMICS; HYDROPHOBICITY; NANOENCAPSULATION; NANOPRECIPITATION; PARTICLE SIZE; PRECIPITATION;

EID: 84904066522     PISSN: 13190164     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsps.2013.12.002     Document Type: Article

References (9)

1. Bala I., Hariharan S., Kumar M.N. PLGA nanoparticles in drug delivery: the state of the art. Crit. Rev. Ther. Drug Carrier Syst. 2004, 21:387-422.
2. Bilati U., Allemann E., Doelker E. Nanoprecipitation versus emulsion-based techniques for the encapsulation of proteins into biodegradable nanoparticles and process-related stability issues. AAPS PharmSciTech 2005, 6:E594-E604.
3. Blaskovich M.A., Sun J., Cantor A., Turkson J., Jove R., Sebti S.M. Discovery of JSI-124 (Cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. Cancer Res. 2003, 63:1270-1279.
4. Jain R.A. The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices. Biomaterials 2000, 21:2475-2490.
5. Jing N., Tweardy D.J. Targeting Stat3 in cancer therapy. Anticancer Drugs 2005, 16:601-607.
6. Makadia H.K., Siegel S.J. Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier. Polymers 2011, 3:1377-1397.
7. Molavi O., Mahmud A., Hamdy S., Hung R.W., Lai R., Samuel J., Lavasanifar A. Development of a poly(d,l-lactic-co-glycolic acid) nanoparticle formulation of STAT3 inhibitor JSI-124: implication for cancer immunotherapy. Mol. Pharm. 2010, 7:364-374.
8. Molavi O., Shayeganpour A., Somayaji V., Hamdy S., Brocks D.R., Lavasanifar A., Kwon G.S., Samuel J. Development of a sensitive and specific liquid chromatography/mass spectrometry method for the quantification of cucurbitacin I (JSI-124) in rat plasma. J. Pharm. Pharm. Sci. 2006, 9:158-164.
9. Mundargi R.C., Babu V.R., Rangaswamy V., Patel P., Aminabhavi T.M. Nano/micro technologies for delivering macromolecular therapeutics using poly(d,l-lactide-co-glycolide) and its derivatives. J. Control Release 2008, 125:193-209.